Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab During ASCT in Multiple Myeloma and Lymphoma
NCT05346809Phase 2Active, not recruiting
- Start
- Mar 2023
- Primary completion
- Jul 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL). Started Mar 2023; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05346809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346809.